Stock Groups

U.S. buys 600,000 more doses of GSK-Vir’s antibody COVID-19 treatment -Breaking

by Mike Robinson

[ad_1]

© Reuters. FILE PHOTO – A GlaxoSmithKline logo (GSK), is seen at GSK’s research center in Stevenage, Britain on November 26, 2019. REUTERS/Peter Nicholls

(Reuters) – GSK, a British pharmaceutical company, and Vir Biotechnology, a U.S.-based partner, announced Tuesday that the United States agreed to purchase 600,000.00 more sotrovimab doses from their COVID-19-based antibody treatment. The amount was not disclosed.

According to drugmakers, the extra doses will be distributed in the United States during the first quarter 2022.

The latest agreement has secured about 1.7 Million doses of the treatment, Xevudy.

Disclaimer: Fusion MediaWe remind you that this site does not contain accurate or real-time data. CFDs include stocks, indexes and futures. Prices are provided not by the exchanges. Market makers provide them. Therefore, prices can be inaccurate and differ from actual market prices. These prices should not be used for trading. Fusion Media does not accept any liability for trade losses that you may incur due to the use of these data.

Fusion MediaFusion Media or any other person involved in the website will not be held responsible for any loss or damage resulting from reliance on this information, including charts, buy/sell signals, and data. Trading the financial markets is one of most risky investment options. Please make sure you are fully aware about the costs and risks involved.

[ad_2]